International Journal of Clinical Research

Objective To explore the clinical efficacy of budesonide combined with compound ipratropium bromide nebulization inhalation in the treatment of emergency severe asthma. Methods 120 severe asthma patients admitted to the emergency department of our hospital from January 2023 to December 2024 were randomly divided into two groups using a random number table. The control group was treated with budesonide single nebulization inhalation, while the observation group was treated with budesonide combined with compound ipratropium bromide nebulization inhalation. Compare the clinical efficacy, symptom relief time, lung function indicators, levels of inflammatory factors, and incidence of adverse reactions between two groups. Results The total effective rate and FEV₁, FEV₁/FVC, PEF indicators of the observation group were higher than those of the control group. The time for relief of wheezing, improvement of dyspnea, cough relief, and the levels of IL-6, TNF - α, and CRP were all shorter in the observation group than in the control group (P<0.05); Comparison of the incidence of adverse reactions between the two groups (P>0.05). Conclusion The combination of budesonide and compound ipratropium bromide nebulization inhalation has significant therapeutic effects on emergency severe asthma, can quickly relieve symptoms, improve lung function, reduce inflammatory reactions, and has good safety. It is worthy of clinical promotion.

Emergency severe asthma; Budesonide; Compound ipratropium bromide; Nebulization inhalation